Is Gilead Sciences (GILD) Stock a Buy?

Gilead Sciences, Inc., is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Gilead Sciences claimed that they are working a cure for COVID-19. Does this make the stock a buy?

Is a Cure Found? 

University of Chicago Medicine analyst saw “Very fast recoveries” in 125 patients suffering from COVID-19 who were taking Gilead Sciences Inc.’s GILD, +9.73% experimental drug redeliver as part of a clinical trial, according to a Thursday night report. This made Gilead Sciences Inc rose almost 9%.

I think that this made Wall Street think that a cure was close and that any good news with a cure or medicine would make any investor less worried. Also, this would make normal people think that the crash was coming to an end and these low prices are a good buy. 

Some analyst says that the price of Gilead Sciences is already baked into the share price. That may be true because the stock is already up 29% year to date. I think that if Gilead Sciences comes up with a cure the stock will go up even more. 


Popular posts from this blog


How to Start Investing in Stocks?